Cassava Sciences | PTIE - Interest Expense On Debt


Cassava Sciences reported $108.37M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Abbott USD 299M 231M Jun/2026
Amgen USD 657M 4M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
Cara Therapeutics -89.64M 128.67M Dec/2025
Cassava Sciences USD 108.37M 396.06M Mar/2026
Eisai JPY 1.55B 117M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Geron USD 7.15M 150K Mar/2026
J&J USD 43M 25M Mar/2026
Merck USD 479M 67M Mar/2026
Novartis USD 343M 39M Mar/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 671M 40M Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025